ArticleVirology journal2009
Consensus siRNA for inhibition of HCV genotype-4 replication.
Article in Virology journal, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 39 citations in OpenAlex.
- Consensus small interfering RNA targeted to stem-loops II and III of IRES structure of 5' UTR effectively inhibits virus replication and translation of HCV sub-genotype 4a isolates from Saudi Arabia.Saudi journal of biological sciences · 2021Article
- Silencing HCV Replication in Its Reservoir.Open access Macedonian journal of medical sciences · 2018Article
- In Silico Design and Experimental Validation of siRNAs Targeting Conserved Regions of Multiple Hepatitis C Virus Genotypes.PloS one · 2016Article
- Trans-splicing group I intron targeting hepatitis C virus IRES mediates cell death upon viral infection in Huh7.5 cells.Virology · 2015Article
- Inhibitory effect of kaolin minerals compound against hepatitis C virus in Huh-7 cell lines.BMC research notes · 2014Article
- Lipid nanoparticles as carriers for RNAi against viral infections: current status and future perspectives.BioMed research international · 2014Review
- Prevalence of hepatitis C virus genotypes in district bannu, khyber pakhtunkhwa, pakistan.Hepatitis research and treatment · 2014Article
- Dynamic interplay between CXCL levels in chronic hepatitis C patients treated by interferon.Virology journal · 2013Article
- Impact of Hepatitis C Virus (HCV) infection on biomolecular markers influencing the pathogenesis of bladder cancer.Infectious agents and cancer · 2013Article
- Development of persistent HCV genotype 3a infection cell culture model in huh-7 cell.Virology journal · 2012Article
- Inhibition of HCV 3a genotype entry through host CD81 and HCV E2 antibodies.Journal of translational medicine · 2011Article
- HCV entry receptors as potential targets for siRNA-based inhibition of HCV.Genetic vaccines and therapy · 2011Article
- Characterization of chronic HCV infection-induced apoptosis.Comparative hepatology · 2011Article
- Glycyrrhizin as antiviral agent against Hepatitis C Virus.Journal of translational medicine · 2011Article
- siRNAs: potential therapeutic agents against hepatitis C virus.Virology journal · 2011Review
- Down-regulation of IRES containing 5'UTR of HCV genotype 3a using siRNAs.Virology journal · 2011Article
- Antiviral activity of Acacia nilotica against Hepatitis C Virus in liver infected cells.Virology journal · 2011Article
- Inhibition of full length hepatitis C virus particles of 1a genotype through small interference RNA.Virology journal · 2011Article
- Role of HCV Core gene of genotype 1a and 3a and host gene Cox-2 in HCV-induced pathogenesis.Virology journal · 2011Article
- Post-transcriptional inhibition of hepatitis C virus replication through small interference RNA.Virology journal · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHCV is circulating as a heterogeneous group of quasispecies. It has been addressed that siRNA can inhibit HCV replication in-vitro using HCV clone and/or replicon which have only one genotype. The current study was conducted to assess whether siRNA can inhibit different HCV genotypes with many quasispecies and to assess whether consensus siRNA have the same effect as regular siRNA.
methodsWe generated two chemically synthesized consensus siRNAs (Z3 and Z5) which cover most known HCV genotype sequences and quasispecies using Ambium system. Highly positive HCV patient's serum with nine quasispecies was transfected in-vitro to Huh-7 cell line which supports HCV genotype-4 replication. siRNA (Z3&Z5) were transfected according to Qiagen Porta-lipid technique and subsequently cultured for eight days. HCV replication was monitored by RT-PCR for detection of plus and minus strands. Real-time PCR was used for quantification of HCV, whereas detection of the viral core protein was performed by western blot.
resultsHCV RNA levels decreased 18-fold (P = 0.001) and 25-fold (P = 0.0005) in cells transfected with Z3 and Z5, respectively, on Day 2 post transfection and continued for Day 3 by Z3 and Day 7 by Z5. Reduction of core protein expression was reported at Day 2 post Z3 siRNA transfection and at Day 1 post Z5 siRNA, which was persistent for Day 4 for the former and for Day 6 for the latter.
conclusionConsensus siRNA could be used as a new molecular target therapy to effectively inhibit HCV replication in the presence of more than one HCV quasispecies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.